Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): Updated real-world (RW) data from US MM-6.

Saulius Girnius,Habte A Yimer,Sudhir Manda,Christopher A. Yasenchak,Veena Charu,Roger M. Lyons,Suman Kambhampati,Reumu E. Birhiray,Haresh Jhangiani,Ralph V. Boccia,Presley Whidden,Kim Bogard,Dasha Cherepanov,Stephen J. Noga,Robert M. Rifkin

Long-term proteasome inhibition in US community multiple myeloma (MM) patients (pts) following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib (I): Updated real-world (RW) data from US MM-6.

2020

Saulius Girnius
Habte A Yimer
Sudhir Manda
Christopher A. Yasenchak
Veena Charu
Roger M. Lyons
Suman Kambhampati
Reumu E. Birhiray
Haresh Jhangiani
Ralph V. Boccia
Presley Whidden
Kim Bogard
Dasha Cherepanov
Stephen J. Noga
Robert M. Rifkin

e19332Background: US MM-6 is investigating iCT from parenteral V-based induction to all-oral I-lenalidomide-dexamethasone (IRd) with the aim of increasing proteasome inhibitor (PI)-based treatment ...

Keywords:

Oncology
Proteasome Inhibition
Bortezomib
Multiple myeloma
Ixazomib
Pathology
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations